AKANDA CORP.

AKAN
NasdaqMedicinal Chemicals & Botanical ProductsX0

+44.5%

since IPO

IPO Price

$12.10

Current Price

$17.49

Return

+44.5%

Market Cap

$9.3M

IPO Date

Jan 21, 2026

Lockup End

Jul 20, 2026

Lockup Status

82days until lockup expires

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price
IPO Price
Lockup End

Performance Summary

First Day
N/A
1 Month
N/A
3 Months
N/A
6 Months
N/A
1 Year
N/A
Since IPO
+44.5%

AKANDA CORP. (AKAN) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

AKANDA CORP. (ticker: AKAN) operates in specialized business operations focused on market development and competitive positioning, establishing itself as a notable participant in the specialized sector. Based in X0 and positioned within the evolving market landscape, the company has developed its operations during a period of industry evolution, technological advancement, and market development and competitive market development. With $9 million in market value, AKANDA CORP. focuses on operational excellence, market focus, and strategic execution while building stakeholder value through strategic execution and market positioning. The company completed its initial public offering on January 21, 2026, pricing shares at $12.10 each during market evolution and focus on sustainable competitive advantages. The IPO received positive institutional support, reflecting market assessment of the company's positioning within the specialized sector and growth prospects. The offering positioned the company to access public capital markets while providing investors with exposure to its operations and strategic development. Market reception reflected investor evaluation of competitive advantages, market positioning, and execution capabilities as key factors in the company's long-term value creation potential. Post-IPO performance has demonstrated strong performance, with the stock currently trading at $17.49, representing a gain of +44.55% from the IPO price. This market execution and competitive positioning demonstrates continued investor confidence in the company's strategic execution within the specialized sector. The solid market acceptance indicates investor evaluation of market positioning, operational execution, and competitive development as critical factors in assessing competitive positioning and sustainable value creation capabilities. Looking ahead, AKANDA CORP.'s lockup period is scheduled to expire July 20, 2026. Given the company's positioning within the specialized sector and its performance trajectory since going public, the lockup expiration will provide valuable insights into management and early investor confidence in strategic direction. The operational characteristics of companies focused on specialized business operations focused on market development and competitive positioning mean that insider decisions often reflect comprehensive assessments of market positioning, operational execution, and competitive development rather than short-term market fluctuations. The lockup milestone indicates management's confidence in executing strategic objectives and creating sustainable value through operational excellence, market focus, and strategic execution within the competitive market landscape.

Performance Overview

Since going public at $12.10 per share on Jan 21, 2026, AKANDA CORP. shares have gained 44.5%, rewarding investors who participated in the IPO. The stock currently trades at $17.49, giving the company a market capitalization of $9.3M.

Lockup Expiration

The lockup period for AKANDA CORP. insiders is set to expire on Jul 20, 2026, which is 82 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.

Industry Context

AKANDA CORP. operates in the Medicinal Chemicals & Botanical Products sector, which has seen varied IPO activity in recent years. The company is headquartered in X0 and is classified under SIC code 2833. Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing AKAN as an investment.

Trading History

AKANDA CORP. is actively trading in the public markets with a current share price of $17.49. The company went public at $12.10 per share, resulting in gains of 44.5% for IPO investors. With a current market capitalization of $9.3M, AKANDA CORP. continues to establish its presence as a publicly traded entity in the Medicinal Chemicals & Botanical Products.

Important Disclaimer

This analysis of AKANDA CORP. (AKAN) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

2
Pre-Expiry Average
Minimal
71
Expiry Day
High
58
Post-Expiry (30d)
High

Activity Heatmap

60 days before/after lockup expiry
Intensity Scale:
Minimal
Low
Moderate
High
Very High
Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Related IPOs

TickerCompanyIndustryIPO DateIPO PriceCurrentReturn
SWRDStewards, Inc.Short-Term Business Credit InstitutionsApr 28, 2026$2.71$2.60-4.1%
COAGHemab Therapeutics Holdings, Inc.Biological Products, (No Diagnostic Substances)Apr 28, 2026N/AN/AN/A
REARare Earths Americas, Inc.Metal MiningApr 28, 2026N/AN/AN/A
QLEPQuantum Leap Acquisition CorpBlank ChecksApr 28, 2026N/AN/AN/A
ASFHASIAFIN HOLDINGS CORP.Services-Business Services, NECApr 28, 2026$0.51$0.51+0.0%
GMRSGMR Solutions Inc.Transportation ServicesApr 28, 2026N/AN/AN/A
IACQIrenic Acquisition Corp.Blank ChecksApr 28, 2026N/AN/AN/A
CXIIChurchill Capital Corp XIIBlank ChecksApr 28, 2026N/AN/AN/A

Related IPO Analysis

KO
By • Founder & Data Analyst